Cargando…
Recent advances in CAR-T cell engineering
Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for relapsed or refractory tumors, particularly for hematological malignancies. Although the initially approved anti-CD19 CAR-T therapy has produced impressive outcomes, setbacks such as high relapse rates and resi...
Autores principales: | Huang, Ruihao, Li, Xiaoping, He, Yundi, Zhu, Wen, Gao, Lei, Liu, Yao, Gao, Li, Wen, Qin, Zhong, Jiang F., Zhang, Cheng, Zhang, Xi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333410/ https://www.ncbi.nlm.nih.gov/pubmed/32616000 http://dx.doi.org/10.1186/s13045-020-00910-5 |
Ejemplares similares
-
CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
por: Huang, Ruihao, et al.
Publicado: (2023) -
Engineering CAR-T cells
por: Zhang, Cheng, et al.
Publicado: (2017) -
P522: OFF-THE-SHELF CD33 CAR-NK CELL THERAPY FOR RELAPSE/REFRACTORY AML: FIRST-IN-HUMAN, PHASE I TRIAL
por: Huang, Ruihao, et al.
Publicado: (2023) -
Recent advances in ocular graft-versus-host disease
por: Cheng, Xianjing, et al.
Publicado: (2023) -
Strategies to enhance CAR-T persistence
por: Liu, Yue, et al.
Publicado: (2022)